Global Gene Therapy Market Information & Analysis (Market Data, Size, and Growth) forecast to 2024

This article provides an overview about the Human Gene Therapy market (Oncology, Cardiovascular, Infectious Diseases, Neurological) – Industry Analysis & Forecast to 2024, there by offering insights on key present growth indicators and forecast indicators such as drivers, restrains, opportunities and trends that are involved in shaping the market.
Gene therapy definition

 

Genes, carried on chromosomes, are the basic physical and functional units of heredity. Notably, gene therapy is the treatment of a disease by replacing, altering, or supplementing a gene that is absent or abnormal, and whose absence or abnormality is causing the disease.

Gene therapy is turning out to be an attractive market for the companies and investors. Furthermore, the market is incessantly gaining popularity amongst the global medical community. The advent of advanced technique for gene transfer has enabled the usage of gene therapy for various new applications. The majority of the gene therapy products are in pre-clinical or clinical research. Till date, there are only four marketed drugs namely, Glybera, Neovasculogen, Gendicine, Rexin-G, and Oncorine. However, these products constitute very less revenue to the gene therapy market. The major revenue of the gene therapy market is generated from the products used in the clinical trials.

 

Request a Sample Report @ https://www.marketresearchfuture.com/ask-sample-request/gene-therapy-market

 

Market Growth Influencer

 

Human gene therapy is a high growth market. The growth of the market is majorly driven by the unavailability of cure for various chronic diseases especially cancer. The medical community is striving to development a proper treatment for cancer through gene therapy. Furthermore, the market is witnessing a precipitous rise in the venture capitalist investments. For instance, recently, Philadelphia based Gene Therapy Company, Spark Therapeutics, raised US$ 72.8 Million from Sofinnova Ventures to launch a gene therapy for genetic form of blindness. Moreover, there is also an increasing incidences of chronic diseases across the globe which is another factor propelling the market growth.
However, stringent regulatory approval process for gene therapy and the high cost of the gene therapy drugs are expected to hinder the growth of the market.  The cost of gene therapy is approximately 1 million. Moreover, the reimbursement scenario of gene therapy is also not well defined due to which people refrain from opting for this therapy.

 

Human Gene Therapy Market: Segmentation

 

For this study, the human gene therapy market is segmented into various segments such as commercialized therapies, product type, indication, and region.

 

On the basis of Commercialized Therapies, the market is segmented into

 

  • Glybera
  • Neovasculogen
  • Gendicine
  • Rexin-G
  • Oncorine

On the basis of Product Type, the market is subdivided into

  • Instruments
  • Reagents,
  • Vectors
    • Adenovirus
    • Retrovirus
    • Plasmid DNA
    • Others

On the basis of Indication, the market is categorized into

 

  • Oncology
  • Cardiovascular Diseases
  • Infectious Diseases
  • Neurological Disorder
  • Genetic Diseases
  • Others

 

  • North America: Human Gene Therapy Market

North America is the largest market for Human Gene Therapy. The USA, was the first country to begin gene therapy clinical trials across the world. The National Institutes of Health (NIH) of the US is playing an important part, as it compiles a database for all completed or ongoing gene therapy trials, and act as a primary source of information for trials performed in the USA.

 

The North American market is expected to witness a high growth due to rising venture capitalist investments, collaborations between the companies for developing new products, and initiation of new gene therapy researches in the region.

Access Report Details @ https://www.marketresearchfuture.com/articles/gene-therapy-market

  • Europe: Human Gene Therapy Market

Europe is the second largest market for gene therapy. The major reason for this high share of the European market is the large number of clinical trials for gene therapy being performed in the region. Furthermore, considering the growing demand of products for gene therapy, the leading players are endeavouring to develop and launch new and innovative products in the market. For instance, in July 2015, AGTC, a clinical-stage biotechnology company, collaborated with Biogen to develop gene-based therapies for multiple ophthalmic diseases.

 

Asia-Pacific: Human Gene Therapy Market

 

Asia-Pacific region is slated to witness the highest growth in coming years. China was the first country to commercialize gene therapy in the year 2003. The region is still engaged in various researches to develop improved and cost effective gene therapies.
Major Player: Human Gene Therapy Market

The prominent players present in the human gene therapy market include Sibiono GeneTech Co. Ltd., Shanghai Sunway Biotech Co. Ltd, Human Stem Cells Institute, UniQure N.V, Spark Therapeutics, LLC, Advantagene Inc, Bluebird Bio, Oxford BioMedica Plc, and Vical Inc amongst others.
About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact:

Akash Anand,

Market Research Future

+1 646 845 9312

Email: akash.anand@marketresearchfuture.com

 

%d bloggers like this: